$18.82
-0.48[-2.49%]
At close: Jun 4
$18.82
0[0.00%]
After Hours: 4:56PM EDT
Syndax Pharmaceuticals
(NASDAQ:SNDX)Latest News for Syndax Pharmaceuticals Stock (NASDAQ:SNDX)
Syndax Pharmaceuticals Stock (NASDAQ: SNDX)
Categories: All
Wednesday, May 29, 2024
Tuesday, May 21, 2024
Thursday, May 09, 2024
- Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30Benzinga Newsdesk - May 9, 2024, 1:52PM
- Stifel Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $40Benzinga Newsdesk - May 9, 2024, 10:05AM
- HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price TargetBenzinga Newsdesk - May 9, 2024, 6:56AM
Wednesday, May 08, 2024
Friday, April 26, 2024
Wednesday, April 03, 2024
Thursday, March 28, 2024
- HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price TargetBenzinga Newsdesk - Mar 28, 2024, 9:53AM
- Syndax Disclosed Completion Of Enrollment In AUGMENT-101 Pivotal Trial Cohort Of Patients With Relapsed/Refractory mNPM1 Acute Myeloid Leukemia & Expects Topline Data In Q1 2024Benzinga Newsdesk - Mar 28, 2024, 7:03AM
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Wednesday, March 20, 2024
Wednesday, February 28, 2024
Tuesday, February 27, 2024
- Syndax Pharmaceuticals Expects $600M In Cash And Equivalents To Provide Runway Through 2026;Benzinga Newsdesk - Feb 27, 2024, 6:15PM
- Syndax Pharmaceuticals: Q4 Earnings InsightsBenzinga Insights - Feb 27, 2024, 4:40PM
- Syndax Pharmaceuticals Q4 2023 GAAP EPS $(1.00) Misses $(0.99) EstimateBenzinga Newsdesk - Feb 27, 2024, 4:37PM
- Earnings Scheduled For February 27, 2024Benzinga Insights - Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Wednesday, January 31, 2024
Tuesday, January 02, 2024
- HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price TargetBenzinga Newsdesk - Jan 2, 2024, 12:07PM
- Syndax Highlights Recent Updates And Anticipated 2024 Milestones; Says Completion Of $230M Follow-on Offering In December Extends Runway Through 2026Benzinga Newsdesk - Jan 2, 2024, 7:05AM
Friday, December 22, 2023
Friday, December 15, 2023
Thursday, December 14, 2023
Monday, December 11, 2023
- What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?Vandana Singh - Dec 11, 2023, 1:47PM
- Syndax Pharmaceuticals shares are trading higher after the company announced data from multiple trials of Revumenib. The company also presented data from its AGAVE-201 trial of axatilimab.Benzinga Newsdesk - Dec 11, 2023, 12:48PM
- Syndax Pharmaceuticals Announced Data From Multiple Trials Of Revumenib In Combination With Standard Of Care Agents In Patients With Nucleophosmin Mutant And KMT2A-rearranged Relapsed/Refractory Acute LeukemiasBenzinga Newsdesk - Dec 11, 2023, 7:31AM
- Incyte And Syndax Present Additional Data From Positive AGAVE-201 Trial At ASH Plenary Session Showing Axatilimab EfficacyBenzinga Newsdesk - Dec 11, 2023, 2:22AM
Tuesday, November 21, 2023
Thursday, November 09, 2023
Thursday, November 02, 2023
Wednesday, November 01, 2023
Thursday, October 26, 2023
Wednesday, October 25, 2023
Tuesday, October 17, 2023
Wednesday, October 11, 2023
Thursday, October 05, 2023
Tuesday, October 03, 2023
Monday, October 02, 2023
- What's Going On With Syndax Pharmaceuticals Stock Monday?Vandana Singh - Oct 2, 2023, 11:51AM
- Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving PremarketLisa Levin - Oct 2, 2023, 8:11AM
- Syndax's AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim AnalysisBenzinga Newsdesk - Oct 2, 2023, 7:08AM
Friday, September 29, 2023
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga Insights - Sep 29, 2023, 5:31PM
- Syndax To Announce Topline Results From Pivotal AUGMENT-101 Trial Of Revumenib In Relapsed/Refractory KMT2Ar Acute Leukemia And Host An Investor Call on Oct. 2Benzinga Newsdesk - Sep 29, 2023, 4:06PM